Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.
about
Current understanding of interactions between nanoparticles and the immune systemPre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategyLow Intensity Ultrasound Mediated Liposomal Doxorubicin Delivery Using Polymer Microbubbles.Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingPharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley ratsFactors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.Physiological, pharmacokinetic and liver metabolism comparisons between 3-, 6-, 12- and 18-month-old male Sprague Dawley rats under ketamine-xylazine anesthesiaInterleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer.A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.Physiological and pharmacokinetic effects of multilevel caging on Sprague Dawley rats under ketamine-xylazine anesthesia.Strategies for triggered drug release from tumor targeted liposomes.Liposomal drug products and recent advances in the synthesis of supercritical fluid-mediated liposomes.Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.Anesthetic and pathological changes following high doses of ketamine and xylazine in Sprague Dawley rats.Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location.Platelet-inspired medicine for tumor therapy.Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production.When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
P2860
Q26345204-297A1A6F-AD07-4FC3-9604-C6422295104EQ28081577-B6532A46-9E57-486B-8A51-42260F86710EQ30359572-F543F522-F4C9-4CA5-92C2-02B0D28A9274Q30456053-3418933F-23DB-4F3F-8948-59F771DF5E73Q34371596-0951D615-4334-4EC8-AA2F-EF139559768BQ35100986-083BE47D-B14D-480C-8E72-E76D446CE236Q36047366-51647EA8-E7E9-4061-8A74-30CB1FB1F11DQ36666343-EE50CADF-0DE3-425B-B1C6-C7F0F7222EBBQ36838928-B8E437B9-3881-409F-9CAF-FC8D4209C3F9Q36867763-6DC6A401-4B6C-4905-A27E-E84FF179D6C6Q37173162-03426B70-C5C6-4712-AA89-8CAEC6320A4BQ37418200-8A26A296-8A92-4980-B803-FA78DB6016E1Q38116638-F04EA7A2-8AEE-4374-A27B-25DDBF3489E9Q38132414-82735E2B-C108-4AA0-9EFA-A011408303DBQ38494470-C458FBC3-CD4F-4200-AEAD-30C163E747E1Q39377012-99A62C61-E030-41CA-8D05-9DA19DE28761Q42046137-7586B1A2-40D0-4AFC-BE0D-F8BB6B66A8FFQ44870836-EDD8DCBD-2BEF-49EC-B36D-3721F8FB52C4Q49234113-C438EE75-E306-4712-AD37-79B42068AC3BQ51038520-C8F8ADB2-4D1B-4F38-8605-F3DB9F33B51DQ51460131-8FF011F3-501F-4DD8-80A8-95709AFA3571Q54207293-E2B31D08-C908-4F6E-AABF-40413B27DCFE
P2860
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.
@en
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.
@nl
type
label
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.
@en
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.
@nl
prefLabel
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.
@en
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.
@nl
P2093
P2860
P1476
Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.
@en
P2093
Keisuke Yoshino
William C Zamboni
P2860
P304
P356
10.3109/08982104.2012.655285
P577
2012-02-15T00:00:00Z